Source: Beximco Pharmaceuticals Ltd. (BXPHARMA) | FY 2019-20 | Page 109

### 28. Other Income

Amount in Taka

| Particulars | Note | July 2019-June 2020 | July 2018-June 2019 |
|---|---|---|---|
| Interest Income | | 20,409,291 | 36,457,527 |
| Dividend Income | | 1,427,930 | 1,491,901 |
| Royalty | | 151,552,031 | 95,941,689 |
| Cash Incentive on Export | | 139,620,667 | 23,646,180 |
| Exchange Rate Fluctuation Gain / (Loss) | | 13,196,829 | (20,010,341) |
| Sale of Miscellaneous Item | | 1,149,448 | 952,663 |
| Profit/(Loss) on Sale of Fixed Assets | | (33,797,892) | 1,438,046 |
| **Total** | | **293,558,304** | **139,917,665** |

### 29. Finance Cost

| Particulars | Note | July 2019-June 2020 | July 2018-June 2019 |
|---|---|---|---|
| Interest on Bank Borrowings | | 787,650,804 | 824,858,713 |
| Interest on Lease Liability | | 28,711,869 | 60,109,947 |
| Interest on Loan from PF, WPPF & Welfare Fund | | 166,837,043 | 128,075,983 |
| Other Bank Charges | | 30,604,369 | 16,717,899 |
| **Total** | | **1,013,804,085** | **1,029,762,542** |

### 30. Income Tax Expenses

This consists of as follows :

| Particulars | Note | July 2019-June 2020 | July 2018-June 2019 |
|---|---|---|---|
| (a) Current Tax | | 1,086,668,418 | 803,760,846 |
| (b) Deferred Tax Expense | | 22,288,436 | 101,901,936 |
| **Total** | | **1,108,956,854** | **905,662,782** |

### 31. Earnings Per Share (EPS)

| Particulars | Note | July 2019-June 2020 | July 2018-June 2019 |
|---|---|---|---|
| (a) Earnings attributable to the Owners of the Company | | 3,514,687,301 | 3,033,402,333 |
| (b) Weighted average number of Shares outstanding during the year | | 405,556,445 | 405,556,445 |
| **Earnings Per Share (EPS)** | | **8.67** | **7.48** |

### 32. Net Asset Value (NAV) Per Share

Amount in Taka

| Particulars | Note | June 30, 2020 | June 30, 2019 |
|---|---|---|---|
| Total Assets | | 50,118,741,940 | 49,214,092,360 |
| Less Total Liabilities | | (17,321,292,327) | (19,349,768,523) |
| Less Non-controlling Interest | | (302,329,006) | (276,006,553) |
| **Equity Attributable to the Owners of the Company** | | **32,495,120,607** | **29,588,317,284** |
| Number of Ordinary Shares | | 405,556,445 | 405,556,445 |
| **Net Asset Value (NAV) Per Share** | | **80.12** | **72.96** |